Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Aug 15;102(4):734–743. doi: 10.1172/JCI2029

Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer.

J B Mackic 1, M Stins 1, J G McComb 1, M Calero 1, J Ghiso 1, K S Kim 1, S D Yan 1, D Stern 1, A M Schmidt 1, B Frangione 1, B V Zlokovic 1
PMCID: PMC508936  PMID: 9710442

Abstract

A soluble monomeric form of Alzheimer's amyloid-beta (1-40) peptide (sAbeta1-40) is present in the circulation and could contribute to neurotoxicity if it crosses the brain capillary endothelium, which comprises the blood-brain barrier (BBB) in vivo. This study characterizes endothelial binding and transcytosis of a synthetic peptide homologous to human sAbeta1-40 using an in vitro model of human BBB. 125I-sAbeta1-40 binding to the brain microvascular endothelial cell monolayer was time dependent, polarized to the apical side, and saturable with high- and low-affinity dissociation constants of 7.8+/-1.2 and 52.8+/-6.2 nM, respectively. Binding of 125I-sAbeta1-40 was inhibited by anti-RAGE (receptor for advanced glycation end products) antibody (63%) and by acetylated low density lipoproteins (33%). Consistent with these data, transfected cultured cells overexpressing RAGE or macrophage scavenger receptor (SR), type A, displayed binding and internalization of 125I-sAbeta1-40. The internalized peptide remains intact > 94%. Transcytosis of 125I-sAbeta1-40 was time and temperature dependent, asymmetrical from the apical to basolateral side, saturable with a Michaelis constant of 45+/-9 nM, and partially sensitive to RAGE blockade (36%) but not to SR blockade. We conclude that RAGE and SR mediate binding of sAbeta1-40 at the apical side of human BBB, and that RAGE is also involved in sAbeta1-40 transcytosis.

Full Text

The Full Text of this article is available as a PDF (544.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Banks W. A., Kastin A. J., Barrera C. M. Delivering peptides to the central nervous system: dilemmas and strategies. Pharm Res. 1991 Nov;8(11):1345–1350. doi: 10.1023/a:1015884603456. [DOI] [PubMed] [Google Scholar]
  2. Banks W. A., Kastin A. J., Horvath A., Michals E. A. Carrier-mediated transport of vasopressin across the blood-brain barrier of the mouse. J Neurosci Res. 1987;18(2):326–332. doi: 10.1002/jnr.490180209. [DOI] [PubMed] [Google Scholar]
  3. Castaño E. M., Prelli F., Soto C., Beavis R., Matsubara E., Shoji M., Frangione B. The length of amyloid-beta in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Implications for the role of amyloid-beta 1-42 in Alzheimer's disease. J Biol Chem. 1996 Dec 13;271(50):32185–32191. doi: 10.1074/jbc.271.50.32185. [DOI] [PubMed] [Google Scholar]
  4. Citron M., Diehl T. S., Gordon G., Biere A. L., Seubert P., Selkoe D. J. Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities. Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13170–13175. doi: 10.1073/pnas.93.23.13170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dehouck B., Fenart L., Dehouck M. P., Pierce A., Torpier G., Cecchelli R. A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J Cell Biol. 1997 Aug 25;138(4):877–889. doi: 10.1083/jcb.138.4.877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dickson D. W. The pathogenesis of senile plaques. J Neuropathol Exp Neurol. 1997 Apr;56(4):321–339. doi: 10.1097/00005072-199704000-00001. [DOI] [PubMed] [Google Scholar]
  7. El Khoury J., Hickman S. E., Thomas C. A., Cao L., Silverstein S. C., Loike J. D. Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature. 1996 Aug 22;382(6593):716–719. doi: 10.1038/382716a0. [DOI] [PubMed] [Google Scholar]
  8. Feldman H. A. Mathematical theory of complex ligand-binding systems of equilibrium: some methods for parameter fitting. Anal Biochem. 1972 Aug;48(2):317–338. doi: 10.1016/0003-2697(72)90084-x. [DOI] [PubMed] [Google Scholar]
  9. Fiala M., Looney D. J., Stins M., Way D. D., Zhang L., Gan X., Chiappelli F., Schweitzer E. S., Shapshak P., Weinand M. TNF-alpha opens a paracellular route for HIV-1 invasion across the blood-brain barrier. Mol Med. 1997 Aug;3(8):553–564. [PMC free article] [PubMed] [Google Scholar]
  10. Gajdusek D. C. Transmissible and non-transmissible amyloidoses: autocatalytic post-translational conversion of host precursor proteins to beta-pleated sheet configurations. J Neuroimmunol. 1988 Dec;20(2-3):95–110. doi: 10.1016/0165-5728(88)90140-3. [DOI] [PubMed] [Google Scholar]
  11. Ghersi-Egea J. F., Gorevic P. D., Ghiso J., Frangione B., Patlak C. S., Fenstermacher J. D. Fate of cerebrospinal fluid-borne amyloid beta-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries. J Neurochem. 1996 Aug;67(2):880–883. doi: 10.1046/j.1471-4159.1996.67020880.x. [DOI] [PubMed] [Google Scholar]
  12. Ghilardi J. R., Catton M., Stimson E. R., Rogers S., Walker L. C., Maggio J. E., Mantyh P. W. Intra-arterial infusion of [125I]A beta 1-40 labels amyloid deposits in the aged primate brain in vivo. Neuroreport. 1996 Nov 4;7(15-17):2607–2611. doi: 10.1097/00001756-199611040-00040. [DOI] [PubMed] [Google Scholar]
  13. Gibson A. E., Noel R. J., Herlihy J. T., Ward W. F. Phenylarsine oxide inhibition of endocytosis: effects on asialofetuin internalization. Am J Physiol. 1989 Aug;257(2 Pt 1):C182–C184. doi: 10.1152/ajpcell.1989.257.2.C182. [DOI] [PubMed] [Google Scholar]
  14. Golden P. L., Maccagnan T. J., Pardridge W. M. Human blood-brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels. J Clin Invest. 1997 Jan 1;99(1):14–18. doi: 10.1172/JCI119125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Goldstein G. W., Betz A. L., Bowman P. D. Use of isolated brain capillaries and cultured endothelial cells to study the blood-brain barrier. Fed Proc. 1984 Feb;43(2):191–195. [PubMed] [Google Scholar]
  16. Hsu H. Y., Hajjar D. P., Khan K. M., Falcone D. J. Ligand binding to macrophage scavenger receptor-A induces urokinase-type plasminogen activator expression by a protein kinase-dependent signaling pathway. J Biol Chem. 1998 Jan 9;273(2):1240–1246. doi: 10.1074/jbc.273.2.1240. [DOI] [PubMed] [Google Scholar]
  17. Jarrett J. T., Lansbury P. T., Jr Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell. 1993 Jun 18;73(6):1055–1058. doi: 10.1016/0092-8674(93)90635-4. [DOI] [PubMed] [Google Scholar]
  18. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  19. Lucarelli M., Gennarelli M., Cardelli P., Novelli G., Scarpa S., Dallapiccola B., Strom R. Expression of receptors for native and chemically modified low-density lipoproteins in brain microvessels. FEBS Lett. 1997 Jan 13;401(1):53–58. doi: 10.1016/s0014-5793(96)01435-4. [DOI] [PubMed] [Google Scholar]
  20. Mackic J. B., Weiss M. H., Miao W., Kirkman E., Ghiso J., Calero M., Bading J., Frangione B., Zlokovic B. V. Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer's amyloid beta peptide in aged squirrel monkey with cerebral amyloid angiopathy. J Neurochem. 1998 Jan;70(1):210–215. doi: 10.1046/j.1471-4159.1998.70010210.x. [DOI] [PubMed] [Google Scholar]
  21. Maness L. M., Banks W. A., Podlisny M. B., Selkoe D. J., Kastin A. J. Passage of human amyloid beta-protein 1-40 across the murine blood-brain barrier. Life Sci. 1994;55(21):1643–1650. doi: 10.1016/0024-3205(94)00331-9. [DOI] [PubMed] [Google Scholar]
  22. Martel C. L., Mackic J. B., Matsubara E., Governale S., Miguel C., Miao W., McComb J. G., Frangione B., Ghiso J., Zlokovic B. V. Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid beta. J Neurochem. 1997 Nov;69(5):1995–2004. doi: 10.1046/j.1471-4159.1997.69051995.x. [DOI] [PubMed] [Google Scholar]
  23. Masters C. L., Simms G., Weinman N. A., Multhaup G., McDonald B. L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A. 1985 Jun;82(12):4245–4249. doi: 10.1073/pnas.82.12.4245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Mattson M. P., Rydel R. E. Alzheimer's disease. Amyloid ox-tox transducers. Nature. 1996 Aug 22;382(6593):674–675. doi: 10.1038/382674a0. [DOI] [PubMed] [Google Scholar]
  25. Miller D. W., Keller B. T., Borchardt R. T. Identification and distribution of insulin receptors on cultured bovine brain microvessel endothelial cells: possible function in insulin processing in the blood-brain barrier. J Cell Physiol. 1994 Nov;161(2):333–341. doi: 10.1002/jcp.1041610218. [DOI] [PubMed] [Google Scholar]
  26. Moss A. L., Ward W. F. Multiple pathways for ligand internalization in rat hepatocytes. I: Effects of anoxia, phenylarsine oxide and monensin. J Cell Physiol. 1991 Nov;149(2):313–318. doi: 10.1002/jcp.1041490219. [DOI] [PubMed] [Google Scholar]
  27. Olefsky J. M., Kao M. Surface binding and rates of internalization of 125I-insulin in adipocytes and IM-9 lymphocytes. J Biol Chem. 1982 Aug 10;257(15):8667–8673. [PubMed] [Google Scholar]
  28. Pardridge W. M. Receptor-mediated peptide transport through the blood-brain barrier. Endocr Rev. 1986 Aug;7(3):314–330. doi: 10.1210/edrv-7-3-314. [DOI] [PubMed] [Google Scholar]
  29. Persidsky Y., Stins M., Way D., Witte M. H., Weinand M., Kim K. S., Bock P., Gendelman H. E., Fiala M. A model for monocyte migration through the blood-brain barrier during HIV-1 encephalitis. J Immunol. 1997 Apr 1;158(7):3499–3510. [PubMed] [Google Scholar]
  30. Poduslo J. F., Curran G. L., Haggard J. J., Biere A. L., Selkoe D. J. Permeability and residual plasma volume of human, Dutch variant, and rat amyloid beta-protein 1-40 at the blood-brain barrier. Neurobiol Dis. 1997;4(1):27–34. doi: 10.1006/nbdi.1997.0132. [DOI] [PubMed] [Google Scholar]
  31. Prior R., D'Urso D., Frank R., Prikulis I., Cleven S., Ihl R., Pavlakovic G. Selective binding of soluble Abeta1-40 and Abeta1-42 to a subset of senile plaques. Am J Pathol. 1996 Jun;148(6):1749–1756. [PMC free article] [PubMed] [Google Scholar]
  32. Schmidt A. M., Hasu M., Popov D., Zhang J. H., Chen J., Yan S. D., Brett J., Cao R., Kuwabara K., Costache G. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8807–8811. doi: 10.1073/pnas.91.19.8807. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D., Sinha S., Schlossmacher M., Whaley J., Swindlehurst C. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature. 1992 Sep 24;359(6393):325–327. doi: 10.1038/359325a0. [DOI] [PubMed] [Google Scholar]
  34. Shoji M., Golde T. E., Ghiso J., Cheung T. T., Estus S., Shaffer L. M., Cai X. D., McKay D. M., Tintner R., Frangione B. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science. 1992 Oct 2;258(5079):126–129. doi: 10.1126/science.1439760. [DOI] [PubMed] [Google Scholar]
  35. Soto C., Frangione B. Two conformational states of amyloid beta-peptide: implications for the pathogenesis of Alzheimer's disease. Neurosci Lett. 1995 Feb 17;186(2-3):115–118. doi: 10.1016/0304-3940(95)11299-c. [DOI] [PubMed] [Google Scholar]
  36. Stins M. F., Gilles F., Kim K. S. Selective expression of adhesion molecules on human brain microvascular endothelial cells. J Neuroimmunol. 1997 Jun;76(1-2):81–90. doi: 10.1016/s0165-5728(97)00036-2. [DOI] [PubMed] [Google Scholar]
  37. Suzuki N., Iwatsubo T., Odaka A., Ishibashi Y., Kitada C., Ihara Y. High tissue content of soluble beta 1-40 is linked to cerebral amyloid angiopathy. Am J Pathol. 1994 Aug;145(2):452–460. [PMC free article] [PubMed] [Google Scholar]
  38. Tabaton M., Nunzi M. G., Xue R., Usiak M., Autilio-Gambetti L., Gambetti P. Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem Biophys Res Commun. 1994 May 16;200(3):1598–1603. doi: 10.1006/bbrc.1994.1634. [DOI] [PubMed] [Google Scholar]
  39. Takakura Y., Audus K. L., Borchardt R. T. Blood-brain barrier: transport studies in isolated brain capillaries and in cultured brain endothelial cells. Adv Pharmacol. 1991;22:137–165. doi: 10.1016/s1054-3589(08)60034-4. [DOI] [PubMed] [Google Scholar]
  40. Terasaki T., Hirai K., Sato H., Kang Y. S., Tsuji A. Absorptive-mediated endocytosis of a dynorphin-like analgesic peptide, E-2078 into the blood-brain barrier. J Pharmacol Exp Ther. 1989 Oct;251(1):351–357. [PubMed] [Google Scholar]
  41. Thomas T., Sutton E. T., Bryant M. W., Rhodin J. A. In vivo vascular damage, leukocyte activation and inflammatory response induced by beta-amyloid. J Submicrosc Cytol Pathol. 1997 Jul;29(3):293–304. [PubMed] [Google Scholar]
  42. Thomas T., Thomas G., McLendon C., Sutton T., Mullan M. beta-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature. 1996 Mar 14;380(6570):168–171. doi: 10.1038/380168a0. [DOI] [PubMed] [Google Scholar]
  43. Wisniewski T., Ghiso J., Frangione B. Biology of A beta amyloid in Alzheimer's disease. Neurobiol Dis. 1997;4(5):313–328. doi: 10.1006/nbdi.1997.0147. [DOI] [PubMed] [Google Scholar]
  44. Yan S. D., Chen X., Fu J., Chen M., Zhu H., Roher A., Slattery T., Zhao L., Nagashima M., Morser J. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature. 1996 Aug 22;382(6593):685–691. doi: 10.1038/382685a0. [DOI] [PubMed] [Google Scholar]
  45. Yan S. D., Fu J., Soto C., Chen X., Zhu H., Al-Mohanna F., Collison K., Zhu A., Stern E., Saido T. An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease. Nature. 1997 Oct 16;389(6652):689–695. doi: 10.1038/39522. [DOI] [PubMed] [Google Scholar]
  46. Zlokovic B. V. Cerebrovascular permeability to peptides: manipulations of transport systems at the blood-brain barrier. Pharm Res. 1995 Oct;12(10):1395–1406. doi: 10.1023/a:1016254514167. [DOI] [PubMed] [Google Scholar]
  47. Zlokovic B. V., Ghiso J., Mackic J. B., McComb J. G., Weiss M. H., Frangione B. Blood-brain barrier transport of circulating Alzheimer's amyloid beta. Biochem Biophys Res Commun. 1993 Dec 30;197(3):1034–1040. doi: 10.1006/bbrc.1993.2582. [DOI] [PubMed] [Google Scholar]
  48. Zlokovic B. V., Martel C. L., Matsubara E., McComb J. G., Zheng G., McCluskey R. T., Frangione B., Ghiso J. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4229–4234. doi: 10.1073/pnas.93.9.4229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Zlokovic B. Can blood-brain barrier play a role in the development of cerebral amyloidosis and Alzheimer's disease pathology. Neurobiol Dis. 1997;4(1):23–26. doi: 10.1006/nbdi.1997.0134. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES